- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Basilea Pharmaceutica AG (BSLN)
Basilea Pharmaceutica AG stock price live, this page displays SIX BSLN stock exchange data. View the BSLN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Basilea Pharmaceutica AG real time stock price chart below.
What Is the Basilea Pharmaceutica AG Stock Price Today?
The Basilea Pharmaceutica AG stock price today is 52.00.
What Is the Stock Symbol for Basilea Pharmaceutica AG?
The stock symbol for Basilea Pharmaceutica AG is ""BSLN.""
What Stock Exchange Does Basilea Pharmaceutica AG Trade On?
Basilea Pharmaceutica AG is listed and trades on the Switzerland stock exchange.
Is Basilea Pharmaceutica AG a Good Stock to Buy?
Determining whether Basilea Pharmaceutica AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BSLN quote. (ISIN: CH0011432447)
What Is the Basilea Pharmaceutica AG Stock Price Today?
The Basilea Pharmaceutica AG stock price today is 52.00.
What Is the Stock Symbol for Basilea Pharmaceutica AG?
The stock symbol for Basilea Pharmaceutica AG is ""BSLN.""
What Stock Exchange Does Basilea Pharmaceutica AG Trade On?
Basilea Pharmaceutica AG is listed and trades on the Switzerland stock exchange.
Is Basilea Pharmaceutica AG a Good Stock to Buy?
Determining whether Basilea Pharmaceutica AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BSLN quote. (ISIN: CH0011432447)
52.00
+0.30(+0.58%)
Closed·
Fair Value
An estimate of a Basilea Pharmaceutica AG's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
51.50
52.40
52 wk Range
37.50
59.70
BSLN Scorecard
Full Analysis
Valuation implies a strong free cash flow yield
Earnings results expected in 3 days
1/2
Fair Value
An estimate of a Basilea Pharmaceutica AG's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
51.5052.40
52 wk Range
37.5059.70
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
BSLN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Basilea Pharmaceutica AG's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
81.34
Upside
+56.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Basilea Pharmaceutica AG Company Profile
Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Compare BSLN to Peers and Sector
Metrics to compare | BSLN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBSLNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 8.2x | −2.8x | −0.5x | |
PEG Ratio | 0.01 | −0.04 | 0.00 | |
Price/Book | 7.8x | 3.1x | 2.6x | |
Price / LTM Sales | 3.0x | 6.8x | 3.3x | |
Upside (Analyst Target) | 29.8% | 25.5% | 40.3% | |
Fair Value Upside | Unlock | 4.0% | 5.1% | Unlock |
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 81.34
(+56.42% Upside)
Earnings
Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Basilea Pharmaceutica AG Trade On?
Basilea Pharmaceutica AG is listed and trades on the Switzerland Stock Exchange stock exchange.
What Is the Stock Symbol for Basilea Pharmaceutica AG?
The stock symbol for Basilea Pharmaceutica AG is "BSLN."
What Is the Basilea Pharmaceutica AG Market Cap?
As of today, Basilea Pharmaceutica AG market cap is 637.94M.
What Is Basilea Pharmaceutica AG's Earnings Per Share (TTM)?
The Basilea Pharmaceutica AG EPS (TTM) is 6.42.
When Is the Next Basilea Pharmaceutica AG Earnings Date?
Basilea Pharmaceutica AG will release its next earnings report on 18 Aug 2025.
From a Technical Analysis Perspective, Is BSLN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Basilea Pharmaceutica AG Stock Split?
Basilea Pharmaceutica AG has split 0 times.
How Many Employees Does Basilea Pharmaceutica AG Have?
Basilea Pharmaceutica AG has 164 employees.
What is the current trading status of Basilea Pharmaceutica AG (BSLN)?
As of 16 Aug 2025, Basilea Pharmaceutica AG (BSLN) is trading at a price of 52.00, with a previous close of 51.70. The stock has fluctuated within a day range of 51.50 to 52.40, while its 52-week range spans from 37.50 to 59.70.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.